By Adam Feuerstein
April 30, 2026
Senior Writer, Biotech
Adam Feuerstein
adam.feuerstein@statnews.com
What does Akeso's primo plenary spot say about its survival data?
Mystery cloaks an ASCO plenary lung cancer survival result.
330 words~2 min read
Related reading
ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny…
Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…
A standing ovation for RevMed, and caution for Akeso
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Exclusive: Akeso pushes back on ASCO questioning of lung cancer drug
Akeso CEO Michelle Xia tells Endpoints the scrutiny of Chinese vs. Western patient data for ivonescimab is overblown, with the…
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos,…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting.…
BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.